Golidocitinib
Golidocitinib is Dizal's JAK1 inhibitor, approved in China in 2024 as the first JAK inhibitor for relapsed peripheral T-cell lymphoma, a cancer with few options after first-line chemotherapy.
Overview
Dizal Pharmaceutical's golidocitinib (DZD4205) was approved by the NMPA in June 2024 for relapsed or refractory peripheral T-cell lymphoma, on the JACKPOT8 trial in which about 44 percent of patients responded. It is the first JAK1-selective inhibitor approved for a cancer. A phase 3 trial testing it as maintenance after first-line therapy is registered.
Selectively inhibits Janus kinase 1, the signalling node that peripheral T-cell lymphoma cells use through the JAK-STAT pathway.
1.Golidocitinib slips into a pocket on its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| CN | 2024 | Relapsed or refractory peripheral T-cell lymphoma |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Golidocitinib" OR ABSTRACT:"Golidocitinib" OR TITLE:"DZD4205" OR ABSTRACT:"DZD4205") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Golidocitinib, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentSoquelitinib
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TreatmentAZD3470
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TreatmentLimertinib
Shares Small-molecule kinase inhibitors and the tag pipeline.
- TreatmentGlumetinib
Shares Small-molecule kinase inhibitors and the tag pipeline.
- TreatmentLerociclib
Shares Small-molecule kinase inhibitors and the tag pipeline.
- TreatmentTunlametinib
Shares Small-molecule kinase inhibitors and the tag pipeline.
- TreatmentGlecirasib
Shares Small-molecule kinase inhibitors and the tag pipeline.
- TreatmentOlverembatinib
Shares Small-molecule kinase inhibitors and the tag pipeline.